View in EDS

HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.

Saved in:
Bibliographic Details
Title: HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.
Authors: Wilcock D; ARUP Laboratories, Salt Lake City, Utah, US., Sirohi D; Department of Pathology, University of California-San Francisco, San Francisco, California, US., Coleman JF; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Adelhardt P; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Kim JT; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Albertson D; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Affolter K; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Beech C; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Jedrzkiewicz J; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Ruano AL; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Cleary AS; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Mahlow J; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Balatico M; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Gulbahce HE; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.
Source: American journal of clinical pathology [Am J Clin Pathol] 2025 Jun 03; Vol. 163 (6), pp. 837-846.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0370470 Publication Model: Print Cited Medium: Internet ISSN: 1943-7722 (Electronic) Linking ISSN: 00029173 NLM ISO Abbreviation: Am J Clin Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39937121
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wilcock+D%22">Wilcock D</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Sirohi+D%22">Sirohi D</searchLink>; Department of Pathology, University of California-San Francisco, San Francisco, California, US.<br /><searchLink fieldCode="AU" term="%22Coleman+JF%22">Coleman JF</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Adelhardt+P%22">Adelhardt P</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Kim+JT%22">Kim JT</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Albertson+D%22">Albertson D</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Affolter+K%22">Affolter K</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Beech+C%22">Beech C</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Jedrzkiewicz+J%22">Jedrzkiewicz J</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Ruano+AL%22">Ruano AL</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Cleary+AS%22">Cleary AS</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Mahlow+J%22">Mahlow J</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Balatico+M%22">Balatico M</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.<br /><searchLink fieldCode="AU" term="%22Gulbahce+HE%22">Gulbahce HE</searchLink>; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370470%22">American journal of clinical pathology</searchLink> [Am J Clin Pathol] 2025 Jun 03; Vol. 163 (6), pp. 837-846.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370470 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1943-7722 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200029173%22">00029173 </searchLink><i>NLM ISO Abbreviation: </i>Am J Clin Pathol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39937121
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/ajcp/aqaf006
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 837
    Titles:
      – TitleFull: HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wilcock D
      – PersonEntity:
          Name:
            NameFull: Sirohi D
      – PersonEntity:
          Name:
            NameFull: Coleman JF
      – PersonEntity:
          Name:
            NameFull: Adelhardt P
      – PersonEntity:
          Name:
            NameFull: Kim JT
      – PersonEntity:
          Name:
            NameFull: Albertson D
      – PersonEntity:
          Name:
            NameFull: Affolter K
      – PersonEntity:
          Name:
            NameFull: Beech C
      – PersonEntity:
          Name:
            NameFull: Jedrzkiewicz J
      – PersonEntity:
          Name:
            NameFull: Ruano AL
      – PersonEntity:
          Name:
            NameFull: Cleary AS
      – PersonEntity:
          Name:
            NameFull: Mahlow J
      – PersonEntity:
          Name:
            NameFull: Balatico M
      – PersonEntity:
          Name:
            NameFull: Gulbahce HE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 06
              Text: 2025 Jun 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1943-7722
          Numbering:
            – Type: volume
              Value: 163
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: American journal of clinical pathology
              Type: main
ResultId 1